EGFR and non-small cell lung carcinoma: Poziotinib (HM781–36B), an irreversible EGFR inhibitor, has also been assessed in a number of phase II clinical trials (NCT03066206, NCT03318939) in patients with NSCLC with Ex20ins mutations.